pharmaphorum January 21, 2025
Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year.
The two filings – both for companies based in Massachusetts and reported by Renaissance Capital – have the usual $100 million placeholder value, but both the number of shares on offer and their price range remain confidential for now.
Odyssey is a specialist in autoimmune and inflammatory diseases. In its provisional prospectus, the start-up says the proceeds of the IPO will go towards phase 2a trials of OD-07656, its small molecule RIPK2 inhibitor. To date, most effort by the pharma industry in this area has focused on RIPK1,...
Today's Sponsors
Today's Sponsor